<DOC>
	<DOC>NCT01248104</DOC>
	<brief_summary>We hypothesize that tranexamic acid administration will be associated with 25% improvement in the volume of blood loss and red blood cell (RBC) administration, with no increase or a decrease in perioperative complications</brief_summary>
	<brief_title>Comparison of Tranexamic to Epsilon Aminocaproic Acid: a Prospective Analysis of Blood Conservation in Cardiac Surgery</brief_title>
	<detailed_description />
	<mesh_term>Aminocaproic Acid</mesh_term>
	<mesh_term>Tranexamic Acid</mesh_term>
	<criteria>1. Is the subject 18 years of age or older? 2. Is the subject scheduled for primary cardiac surgery utilizing cardiopulmonary bypass(CPB)? 3. Is the subject more than 30 kg ( 66 lbs)? 4. Does subject understand English? 1. Does the subject have existing coagulation defects (INR &gt; 1.5, platelets &lt; 100 ? 2. Does the subject have renal failure (defined as BUN/Cr ratio 20:1 ? 3. Does the subject have severe liver disease (AST &amp; ALT&gt; 3x normal) ? 4. Is the subject having emergency cardiac surgery, complex aortic surgery, combination valve/CABG surgeries, or redo cardiac surgery? 5. Is the subject having any procedure where CPB is not anticipated? 6. Is the patient weight greater than 150 kg?</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Cardiac Surgery</keyword>
	<keyword>Antifibrinolytic agents</keyword>
	<keyword>Blood transfusion</keyword>
	<keyword>epsilon aminocaproic acid</keyword>
	<keyword>tranexamic acid</keyword>
</DOC>